I was at #ICSSOA2017 conference this week and thoroughly enjoyed it. While I was taking my usual in-conference scribbles, people became particularly interested in a the couple of lines I posted from a very engaging ‘myth busting’ talk given by Dr Chris Laing (@DrChrisLaing). That original scribble is posted at the end of this blog.
In the interest of follow up, I decided to sit down and read one of the main references for this talk today, so I could produce something a little more focused on it. I think at the very least it certainly suggests that, although a prospective trial would likely be required to shift many years of what seems like dogma, such a trial would surely be ethical. I also agree with the authors who suggest that, within the context of paying heed to and managing other risk factors for AKI, clinicians could now shift the weight of importance that they give to IV contrast in situations where they are weighing up the risk of AKI against achieving appropriate diagnosis for a patients.
As always discussion welcome!
(the reference linked above is open access, so please have a look too!)